Virpax Other Current Liab from 2010 to 2025
| VRPX Stock | USD 1.55 0.06 3.73% |
Other Current Liabilities | First Reported 2010-12-31 | Previous Quarter 2.5 B | Current Value 2.6 B | Quarterly Volatility 864.2 M |
Check Virpax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virpax Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Selling General Administrative of 6.6 B or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Virpax financial statements analysis is a perfect complement when working with Virpax Pharmaceuticals Valuation or Volatility modules.
Virpax | Other Current Liab |
Latest Virpax Pharmaceuticals' Other Current Liab Growth Pattern
Below is the plot of the Other Current Liab of Virpax Pharmaceuticals over the last few years. It is Virpax Pharmaceuticals' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Virpax Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Other Current Liab | 10 Years Trend |
|
Other Current Liab |
| Timeline |
Virpax Other Current Liab Regression Statistics
| Arithmetic Mean | 317,900,653 | |
| Geometric Mean | 3,188,792 | |
| Coefficient Of Variation | 271.86 | |
| Mean Deviation | 553,301,924 | |
| Median | 754,224 | |
| Standard Deviation | 864,243,704 | |
| Sample Variance | 746917.2T | |
| Range | 2.6B | |
| R-Value | 0.58 | |
| Mean Square Error | 534812.2T | |
| R-Squared | 0.33 | |
| Significance | 0.02 | |
| Slope | 104,549,261 | |
| Total Sum of Squares | 11203757.7T |
Virpax Other Current Liab History
About Virpax Pharmaceuticals Financial Statements
Virpax Pharmaceuticals investors use historical fundamental indicators, such as Virpax Pharmaceuticals' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virpax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Current Liabilities | 2.5 B | 2.6 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Virpax Stock Analysis
When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.